These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9181928)

  • 21. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ BCG-immunotherapy and bladder cancer].
    Rischmann P
    Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
    [No Abstract]   [Full Text] [Related]  

  • 23. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
    Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
    Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance therapy with bacillus Calmette-Guerin in patients with superficial bladder cancer.
    Swibold LK
    Urol Nurs; 1999 Mar; 19(1):38-41. PubMed ID: 10373991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
    Decobert M; Larue H; Bergeron A; Harel F; Pfister C; Rousseau F; Lacombe L; Fradet Y
    J Urol; 2006 Apr; 175(4):1506-11. PubMed ID: 16516037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The management of superficial bladder cancer.
    Oosterlinck W
    BJU Int; 2001 Jan; 87(2):135-40. PubMed ID: 11167630
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining bacillus Calmette-Guerin refractory superficial bladder tumors.
    Herr HW; Dalbagni G
    J Urol; 2003 May; 169(5):1706-8. PubMed ID: 12686813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loco-regional immunotherapy for bladder cancer.
    Kuss R; Haertig A
    Prog Clin Biol Res; 1984; 162B():321-33. PubMed ID: 6504902
    [No Abstract]   [Full Text] [Related]  

  • 34. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
    Iavarone C; Minocchi L; Arecchi S; Nicolucci D; Porcelli C; D'orazi V; Greco L; Stio F; Martino G; Messinetti S
    G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
    [No Abstract]   [Full Text] [Related]  

  • 35. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
    Herr HW; Dalbagni G
    BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin.
    O'Donnell M
    J Urol; 2006 Apr; 175(4):1197-8. PubMed ID: 16515958
    [No Abstract]   [Full Text] [Related]  

  • 37. Miliary tuberculosis of the lung in a patient treated with bacillus Calmette-Guerin for superficial bladder cancer.
    Iantorno R; Nicolai M; Storto ML; Ciccotosto C; Cipollone G; Mastroprimiano G; Tenaglia RL
    J Urol; 1998 May; 159(5):1639-40. PubMed ID: 9554372
    [No Abstract]   [Full Text] [Related]  

  • 38. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
    Patard JJ; Chopin DK
    Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of intravesical Bacillus Calmette-Guerin instillations on the expression of inducible nitric oxide synthase in humans.
    Mitropoulos D; Petsis D; Kyroudi-Voulgari A; Kouloukoussa M; Zervas A; Dimopoulos C
    Nitric Oxide; 2005 Aug; 13(1):36-41. PubMed ID: 15964223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.